Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Increased expression of fatty acid synthase in human aberrant crypt foci: possible target for colorectal cancer prevention.

Kearney KE, Pretlow TG, Pretlow TP.

Int J Cancer. 2009 Jul 1;125(1):249-52. doi: 10.1002/ijc.24356.

2.

In Vivo Small Animal Imaging for Early Assessment of Therapeutic Efficacy of Photodynamic Therapy for Prostate Cancer.

Fei B, Wang H, Chen X, Meyers J, Mulvihill J, Feyes D, Edgehouse N, Duerk JL, Pretlow TG, Oleinick NL.

Proc SPIE Int Soc Opt Eng. 2007 Mar 29;6511. doi: 10.1117/12.708718.

3.

Loss of heterozygosity in human aberrant crypt foci (ACF), a putative precursor of colon cancer.

Luo L, Shen GQ, Stiffler KA, Wang QK, Pretlow TG, Pretlow TP.

Carcinogenesis. 2006 Jun;27(6):1153-9. Epub 2006 Feb 12.

PMID:
16474178
4.

Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?

Pretlow TP, Pretlow TG.

Biochim Biophys Acta. 2005 Nov 25;1756(2):83-96. Epub 2005 Jul 18. Review.

PMID:
16219426
5.

Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological grade.

Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT.

Cancer Res. 2004 Jul 15;64(14):4774-82.

6.

Spontaneous aberrant crypt foci in Apc1638N mice with a mutant Apc allele.

Pretlow TP, Edelmann W, Kucherlapati R, Pretlow TG, Augenlicht LH.

Am J Pathol. 2003 Nov;163(5):1757-63.

7.

Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line.

Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ.

Cancer Res. 2002 Nov 15;62(22):6606-14.

8.

Beta-catenin expression is altered in human colonic aberrant crypt foci.

Hao XP, Pretlow TG, Rao JS, Pretlow TP.

Cancer Res. 2001 Nov 15;61(22):8085-8.

10.
11.

Full-length cDNA sequence and genomic organization of human NKX3A - alternative forms and regulation by both androgens and estrogens.

Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Kizildag S, Pretlow TG, Saatcioglu F.

Gene. 2000 Dec 30;260(1-2):25-36.

PMID:
11137288
12.

An efficient procedure for cloning hormone-responsive genes from a specific tissue.

Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Pretlow TG, Saatcioglu F.

DNA Cell Biol. 2000 Aug;19(8):499-506.

PMID:
10975467
13.

Prostate cancer and other xenografts from cells in peripheral blood of patients.

Pretlow TG, Schwartz S, Giaconia JM, Wright AL, Grimm HA, Edgehouse NL, Murphy JR, Markowitz SD, Jamison JM, Summers JL, Hamlin CR, MacLennan GT, Resnick MI, Pretlow TP, Connell CF.

Cancer Res. 2000 Aug 1;60(15):4033-6.

14.

Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions.

Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC, Pretlow TP.

Cancer Res. 2000 Jan 1;60(1):18-21.

15.

Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

Bubendorf L, Kolmer M, Kononen J, Koivisto P, Mousses S, Chen Y, Mahlamäki E, Schraml P, Moch H, Willi N, Elkahloun AG, Pretlow TG, Gasser TC, Mihatsch MJ, Sauter G, Kallioniemi OP.

J Natl Cancer Inst. 1999 Oct 20;91(20):1758-64.

PMID:
10528027
16.

Re: Dietary fat, calories, and prostate cancer risk.

Pretlow TG.

J Natl Cancer Inst. 1999 Oct 6;91(19):1691A-1692. No abstract available.

PMID:
10511605
17.

A new human prostate carcinoma cell line, 22Rv1.

Sramkoski RM, Pretlow TG 2nd, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW.

In Vitro Cell Dev Biol Anim. 1999 Jul-Aug;35(7):403-9.

PMID:
10462204
18.

Molecular cytogenetic studies of a serially transplanted primary prostatic carcinoma xenograft (CWR22) and four relapsed tumors.

Kochera M, Depinet TW, Pretlow TP, Giaconia JM, Edgehouse NL, Pretlow TG, Schwartz S.

Prostate. 1999 Sep 15;41(1):7-11.

PMID:
10440870
19.

Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.

Gregory CW, Kim D, Ye P, D'Ercole AJ, Pretlow TG, Mohler JL, French FS.

Endocrinology. 1999 May;140(5):2372-81.

PMID:
10218991
20.

Changes in cyclin dependent kinase inhibitors p21 and p27 during the castration induced regression of the CWR22 model of prostatic adenocarcinoma.

Myers RB, Oelschlager DK, Coan PN, Frost AR, Weiss HL, Manne U, Pretlow TG, Grizzle WE.

J Urol. 1999 Mar;161(3):945-9.

PMID:
10022731
21.

Overexpression of cyclin D1 is rare in human prostate carcinoma.

Gumbiner LM, Gumerlock PH, Mack PC, Chi SG, deVere White RW, Mohler JL, Pretlow TG, Tricoli JV.

Prostate. 1999 Jan 1;38(1):40-5.

PMID:
9973108
22.

The identification of monoclonality in human aberrant crypt foci.

Siu IM, Robinson DR, Schwartz S, Kung HJ, Pretlow TG, Petersen RB, Pretlow TP.

Cancer Res. 1999 Jan 1;59(1):63-6.

23.

Providing human tissues for research: how to establish a program.

Grizzle WE, Aamodt R, Clausen K, LiVolsi V, Pretlow TG, Qualman S.

Arch Pathol Lab Med. 1998 Dec;122(12):1065-76.

PMID:
9870854
24.

Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes.

Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS.

Cancer Res. 1998 Dec 15;58(24):5718-24.

25.

Workgroup 2: human xenograft models of prostate cancer.

Stearns ME, Ware JL, Agus DB, Chang CJ, Fidler IJ, Fife RS, Goode R, Holmes E, Kinch MS, Peehl DM, Pretlow TG 2nd, Thalmann GN.

Prostate. 1998 Jun 15;36(1):56-8. No abstract available.

PMID:
9650917
26.

Putative preneoplastic changes identified by enzyme histochemical and immunohistochemical techniques.

Pretlow TP, Pretlow TG.

J Histochem Cytochem. 1998 May;46(5):577-83. Review.

PMID:
9606105
28.

Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer.

Dawson DM, Lawrence EG, MacLennan GT, Amini SB, Kung HJ, Robinson D, Resnick MI, Kursh ED, Pretlow TP, Pretlow TG.

J Natl Cancer Inst. 1998 Apr 1;90(7):519-23.

PMID:
9539247
29.

Evidence of independent origin of multiple tumors from patients with prostate cancer.

Cheng L, Song SY, Pretlow TG, Abdul-Karim FW, Kung HJ, Dawson DV, Park WS, Moon YW, Tsai ML, Linehan WM, Emmert-Buck MR, Liotta LA, Zhuang Z.

J Natl Cancer Inst. 1998 Feb 4;90(3):233-7.

PMID:
9462681
30.

ErbB kinases and NDF signaling in human prostate cancer cells.

Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.

Oncogene. 1997 Nov 27;15(22):2705-16.

31.

Identification of dysplasia in human colonic aberrant crypt foci.

Siu IM, Pretlow TG, Amini SB, Pretlow TP.

Am J Pathol. 1997 May;150(5):1805-13.

32.

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells.

Tan J, Sharief Y, Hamil KG, Gregory CW, Zang DY, Sar M, Gumerlock PH, deVere White RW, Pretlow TG, Harris SE, Wilson EM, Mohler JL, French FS.

Mol Endocrinol. 1997 Apr;11(4):450-9.

PMID:
9092797
33.

Ultrasound reflections fail to reflect the histopathology of the prostate.

Tobocman W, Resnick MI, Pretlow TG.

Prostate. 1997 Jan 1;30(1):33-40.

PMID:
9018333
34.

Altered expression of CD44 in human prostate cancer during progression.

Nagabhushan M, Pretlow TG, Guo YJ, Amini SB, Pretlow TP, Sy MS.

Am J Clin Pathol. 1996 Nov;106(5):647-51.

PMID:
8929476
35.

Human aberrant crypt foci with carcinoma in situ from a patient with sporadic colon cancer.

Konstantakos AK, Siu IM, Pretlow TG, Stellato TA, Pretlow TP.

Gastroenterology. 1996 Sep;111(3):772-7.

PMID:
8780584
36.

CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar.

Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG.

Cancer Res. 1996 Jul 1;56(13):3042-6.

37.

Expression of E-cadherin in primary and metastatic prostate cancer.

Cheng L, Nagabhushan M, Pretlow TP, Amini SB, Pretlow TG.

Am J Pathol. 1996 May;148(5):1375-80.

38.

CWR22 xenograft as an ex vivo human tumor model for prostate cancer gene therapy.

Cheng L, Sun J, Pretlow TG, Culp J, Yang NS.

J Natl Cancer Inst. 1996 May 1;88(9):607-11.

PMID:
8609662
39.

Prostatic intraepithelial neoplasia and other changes during promotion and progression.

Pretlow TG, Nagabhushan M, Pretlow TP.

Pathol Res Pract. 1995 Sep;191(9):842-9. Review.

PMID:
8606863
40.

Histocultures of human prostate tissues for pharmacologic evaluation.

Wientjes MG, Pretlow TG, Badalament RA, Burgers JK, Au JL.

J Urol. 1995 Apr;153(4):1299-302.

PMID:
7532726
41.

Organ culture of benign, aging, and hyperplastic human prostate.

Pretlow TG, Yang B, Pretlow TP.

Microsc Res Tech. 1995 Mar 1;30(4):271-81. Review.

PMID:
7541675
42.

A novel approach to the characterization of whole prostate pathology in glycol methacrylate.

Monger LE Jr, Nagabhushan M, Pretlow TG, Pretlow TP.

Am J Pathol. 1994 Jul;145(1):54-60.

43.

The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials.

Bostwick DG, Burke HB, Wheeler TM, Chung LW, Bookstein R, Pretlow TG, Nagle RB, Montironi R, Lieber MM, Veltri RW, et al.

J Cell Biochem Suppl. 1994;19:283-9. Review.

PMID:
7529857
44.

Putative preneoplastic foci in the human prostate.

Pretlow TG, Nagabhushan M, Sy M, Guo Y, Pretlow TP.

J Cell Biochem Suppl. 1994;19:224-31. Review.

PMID:
7529854
46.

Study of activities of arginase, hexosaminidase, and leucine aminopeptidase in prostate fluid.

Vafa AZ, Grover PK, Pretlow TG, Resnick MI.

Urology. 1993 Aug;42(2):138-43.

PMID:
7690169
47.

A better defined medium for human prostate cancer cells.

Pretlow TG, Ogrinc GS, Amini SB, Delmoro CM, Molkentin KF, Willson JK, Pretlow TP.

In Vitro Cell Dev Biol Anim. 1993 Jul;29A(7):528-30. No abstract available.

PMID:
8354663
48.
49.

Xenografts of primary human prostatic carcinoma.

Pretlow TG, Wolman SR, Micale MA, Pelley RJ, Kursh ED, Resnick MI, Bodner DR, Jacobberger JW, Delmoro CM, Giaconia JM, et al.

J Natl Cancer Inst. 1993 Mar 3;85(5):394-8.

PMID:
8433392
50.

The Cooperative Human Tissue Network. An update.

LiVolsi VA, Clausen KP, Grizzle W, Newton W, Pretlow TG 2nd, Aamodt R.

Cancer. 1993 Feb 15;71(4):1391-4.

PMID:
8435815

Supplemental Content

Loading ...
Support Center